Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Bristol-Myers Squibb Oncology Deal Yields First Targets

NEW YORK, Dec. 13 - Exelixis and Bristol-Myers Squibb said they have identified and selected the first small molecule cancer targets to result from a broad oncology collaboration announced five months ago.

Exelixis, which uses invertebrate and vertebrate gene knockout models to study how certain genes interact in cancer cells to identify particular genes that help suppress tumor growth, said it had identified ways that tumor cells “evade normal growth control mechanisms.”

The targets Exelixis discovered come from genes that interact with the p53 tumor suppressor and will now become the focus of drug discovery efforts at both Exelixis and Bristol-Myers Squibb.

"We are excited by the identification of new and potentially druggable mechanisms by which tumor suppressors function in the deregulated growth of tumors," Robert Kramer, head of Bristol-Myers Squibb’s Lawrenceville biology site.

In July, the two companies entered into a far-reaching oncology collaboration. Bristol-Myers made a $20 million equity investment in Exelixis, and a $5 million upfront payment from Bristol-Myers for Exelixis' functional genomics services. As a result of the transaction Bristol-Myers acquired 600,600 shares of Exelixis stock, or about one percent of the outstanding shares.

In addition, Bristol-Myers agreed to pay Exelixis $3 million a year for at least three years.

Each company has the option to obtain worldwide rights to equal numbers of validated targets arising from the collaboration.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.